Clobazam
Approved · FDAAlso known as Onfi, Sympazan, 1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine, Clobazamum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Label change: CLOBAZAM (ANDA213039)
Label change: CLOBAZAM (ANDA213039)
Approval: CLOBAZAM (ANDA213039)
Use of Clobazam in Treating Anxiety Comorbid With Pediatric Epilepsy
Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- Epilepsy & behavior : E&B1
- Conry J1
- Drummond R1
- Isojarvi J1
- Kernitsky L1
- Lee D1
- Mitchell W1
- Ng YT1
- Owen R1
- University of Oklahoma Health Sciences Center1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.